Basel - Events at Quotient Sciences

Rationalizing the Preclinical-Clinical Hurdle – How to Overcome the Toxicology Exposure Challenge

Basel, Switzerland | 28 May 2024

Join our speaker, Dr. Andrew Parker as he delves into the regulatory framework and the needs of enabling technologies for poorly soluble molecules.  

In this presentation, Dr. Andrew Parker, Senior Drug Development Consultant, will discuss considerations when navigating the pre-clinical to clinical transition, exploring regulatory expectations, enabling technologies for poorly soluble molecules, and other topics.

He will review the solutions that our team have developed to help customers successfully navigate through development milestones, leveraging the Quotient Sciences Translational Pharmaceutics® platform. He will share the rationale for assessing amorphous solid dispersions when compared with lipidics and size reduction and show how these can be easily translated into fit-for-purpose, first-in-human (FIH) presentations suitable for oral administration and enabling dose escalation.

Key learning objectives:

  • How to identify the best development strategy, technology(s) and candidate(s), demonstrate solubility improvement and stability
  • Justify the selection of prototypes as suitable for animal testing and potentially improving exposure to meet toxicology multiples required to justify entering an FIH study
  • Where to invest from the early stage, modularity of the preclinical screen, and how it can be refined based on your needs

Tuesday, May 28, 2024

Arrival 10:30-11:00 AM
Seminar 11:00-12:00 PM
Lunch & Networking 12:00-1:00 PM

Raddison Blu Hotel
Steinentorstrasse 25, 4051
Basel, Switzerland

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.

Register now
Raddison Blu Hotel
Steinentorstrasse 25, 4051
Basel, Switzerland

Meet our experts:

We look forward to meeting you at our seminar taking place in Basel, Switzerland.

David Ross

Senior Director Business Development (Europe)

David has over 18 years of career experience within the pharmaceutical industry across various disciplines, sectors, and therapeutic areas.

Contact Us
Dr. Andrew Parker

Senior Drug Development Consultant

Dr. Andrew Parker has two decades of experience in the pharmaceutical industry, spanning from preclinical development, through ear...

Contact Us

More insight from our experts:

Read More
Dr. Andrew Lewis Reflecting on Scientific Achievements in 2023 By: Dr. Andrew Lewis
Read More
Paige Bellis, Bioanalysis, Bioanalytical Method Development, Alnwick, Careers Spotlight on ICP-MS Bioanalysis at Quotient Sciences By: Paige Bellis
Read More